Clinical Trial

Y-90 SIRT for Unresectable HCC Larger Than 7cm

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II clinical study to evaluate the efficacy and safety of SIRT in patients with HCC greater than 7 cm. After enrollment, patients received yttrium-90 selective internal radiation therapy. The primary endpoint of the study is objective reponse rate (ORR) as assessed by mRECIST. Secondary endpoints were: objective response rate (ORR) as assessed by RECIST 1.1, disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DOR), overall survival (OS), and safety (incidence and severity of adverse events).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-24.
Status change: Not Yet Recruiting → Recruiting 2025-01-26
Trial Details
NCT Number NCT06707233
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Hepatocellular Carcinoma Non-Resectable
Enrollment 33 participants
Start Date 2024-12-01
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-28